Polyclonal antibodies covering the 17 most common cancer types
Atlas Antibodies offers 21,000 Triple A Polyclonals, each supplied with more than 500 annotated IHC images, including images from cancerous tissues.
The antibodies have been used for staining 48 normal human tissue samples and human cancer samples covering the 17 most common cancer types and up to 12 patients for each cancer type.
Cancer Stem Cell Markers
Cancer stem cells (CSCs) are a small number of cells that drive the tumor’s initiation, growth and metastasis, and may cause relapse.
Due to their importance, several biomarkers that characterize CSCs have been identified, allowing diagnostic, therapeutic, and prognostic predictions.
Atlas Antibodies offers antibodies targeting several proteins relevant as CSC markers, focusing on solid and hematological cancers.
Ovarian Cancer Markers
Atlas Antibodies has released new PrecisA Monoclonal antibodies targeting 23 proteins relevant to ovarian cancers (such as high and low-grade serous, endometrioid, clear cell, and mucinous carcinomas), with diagnostic and prognostic values validated on human cancer tissues.
Download White Paper
Markers in Gynecological Cancers
Of all the gynecological cancers, only cervical cancer has screening tests to find this cancer early, when treatment can be most effective. Therefore, there is a high demand to identify biomarkers specific to these diseases for screening for early detection and new therapeutic targets.
Mechanisms in Cancer
PrecisA Monoclonals and Triple A Polyclonals are in-house developed antibodies for dedicated targets.
Atlas Antibodies selects clones recognizing unique non-overlapping epitopes and/or isotypes.
Our antibodies are covering wide range of cellular processes in cancer: Cell Cycle Markers, Cell Death Markers, Metastasis Markers, Tumor Angiogenesis and Lymphoangiogenesis Markers, Tumor Proliferation Markers.
Glioma Markers
Atlas Antibodies offers antibodies targeting the glioma proteome, the tumor microenvironment and the key molecular markers for glioma classification.
Markers for Glioma Classification
ATRX has become a routine marker for the classification of gliomas and is most often used in combination with various other markers, such as IDH1 and GFAP.
Neuroendocrine Neoplasms Markers
Neuroendocrine neoplasms (NENs) constitute a group of tumors that derive from the sensory and secretory neuroendocrine cells of the diffuse endocrine system.
There is an unmet need for accurate biomarkers that can be used for NEN diagnosis, prognosis and follow-up, therapy stratification, and evaluation of treatment response.
Discover our newly released PrecisA Monoclonals useful for the immunohistological profiling of NENs.
Oncology Biomarkers
Atlas Antibodies recognizes the need for new biomarkers to provide a more accurate diagnosis and a better assessment of patient prognosis, ultimately leading to a more individualized treatment.
Together with our research partners in the Human Protein Atlas project, we are in a unique position to perform antibody-based biomarker discovery.
Learn about Atlas Antibodies oncology biomarkers T-PIT / TBX19, SATB2, PODXL and RBM3.
GPCRs Markers
G protein-coupled receptors (GPCRs) allow the communication between the environment and the cell’s interior: they transduce extracellular stimuli into intracellular signals.
GPCRs play an essential role in different physiological functions and have been well documented in many forms of cancer, contributing to cancer proliferation, angiogenesis, invasion, and metastasis.
Colorectal Cancer
A large number of our antibodies are relevant for scientists studying colorectal cancer. In this brochure, we catalog our antibodies related to the field of colorectal cancer research together with publication references.
Download White Paper
Breast Cancer
A wide range of our antibodies is used by scientists working to understand breast cancer. In this brochure, we catalog our antibodies related to the field of breast cancer research together with publication references.
Epithelial-to-Mesenchymal Transition Markers
The Epithelial-to-Mesenchymal Transition (EMT) is a process that normally occurs during embryogenesis, but is also present in wound healing and cancer progression of epithelial tumors.
The EMT marker antibody panel consists of PrecisA Monoclonals manufactured by Atlas Antibodies targeting key EMT markers for cell junctions, cytoskeletal changes, transcription regulation and migration/motility.
